Programmed cell death protein 1 (PD-1), programmed cell death 1 ligand 1 (PD-L1) and cytotoxic T lymphocyte associated protein 4 (CTLA-4) checkpoint inhibitors are important milestones in the drug development for cancer therapy (1). This evidence concerns the gene CD274 and cancer.